Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity.

Tye-Din JA, Skodje GI, Sarna VK, Dzuris JL, Russell AK, Goel G, Wang S, Goldstein KE, Williams LJ, Sollid LM, Lundin KE, Anderson RP.

United European Gastroenterol J. 2020 Feb;8(1):108-118. doi: 10.1177/2050640619874173. Epub 2019 Sep 3.

PMID:
32213060
2.

Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.

Goel G, Daveson AJM, Hooi CE, Tye-Din JA, Wang S, Szymczak E, Williams LJ, Dzuris JL, Neff KM, Truitt KE, Anderson RP.

Clin Exp Immunol. 2020 Jan;199(1):68-78. doi: 10.1111/cei.13369. Epub 2019 Oct 1.

PMID:
31505020
3.

Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease.

Tye-Din JA, Daveson AJM, Ee HC, Goel G, MacDougall J, Acaster S, Goldstein KE, Dzuris JL, Neff KM, Truitt KE, Anderson RP.

Aliment Pharmacol Ther. 2019 Oct;50(8):901-910. doi: 10.1111/apt.15477. Epub 2019 Sep 4.

PMID:
31483515
4.

Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease.

Goel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, Sarna VK, Wang S, Goldstein KE, Dzuris JL, Williams LJ, Xavier RJ, Lundin KEA, Jabri B, Sollid LM, Anderson RP.

Sci Adv. 2019 Aug 7;5(8):eaaw7756. doi: 10.1126/sciadv.aaw7756. eCollection 2019 Aug.

5.

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

Daveson AJM, Ee HC, Andrews JM, King T, Goldstein KE, Dzuris JL, MacDougall JA, Williams LJ, Treohan A, Cooreman MP, Anderson RP.

EBioMedicine. 2017 Dec;26:78-90. doi: 10.1016/j.ebiom.2017.11.018. Epub 2017 Nov 22.

6.

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.

Goel G, King T, Daveson AJ, Andrews JM, Krishnarajah J, Krause R, Brown GJE, Fogel R, Barish CF, Epstein R, Kinney TP, Miner PB Jr, Tye-Din JA, Girardin A, Taavela J, Popp A, Sidney J, Mäki M, Goldstein KE, Griffin PH, Wang S, Dzuris JL, Williams LJ, Sette A, Xavier RJ, Sollid LM, Jabri B, Anderson RP.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):479-493. doi: 10.1016/S2468-1253(17)30110-3. Epub 2017 May 11.

7.

A retro-inverso α-melanocyte stimulating hormone analog with MC1R-binding selectivity.

Weeden T, Stefano J, Duan S, Edling A, Hou L, Chuang WL, Perricone MA, Pan C, Dzuris JL.

J Pept Sci. 2011 Jan;17(1):47-55. doi: 10.1002/psc.1306. Epub 2010 Oct 25.

PMID:
21171144
8.

Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion.

LaCorcia G, Swistak M, Lawendowski C, Duan S, Weeden T, Nahill S, Williams JM, Dzuris JL.

Transplantation. 2009 Apr 15;87(7):966-74. doi: 10.1097/TP.0b013e31819c84b8.

PMID:
19352114
9.

Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution.

Sette A, Sidney J, Livingston BD, Dzuris JL, Crimi C, Walker CM, Southwood S, Collins EJ, Hughes AL.

Immunogenetics. 2003 Mar;54(12):830-41. Epub 2003 Feb 14.

PMID:
12671733
10.
11.

Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Dzuris JL, Sidney J, Horton H, Correa R, Carter D, Chesnut RW, Watkins DI, Sette A.

J Virol. 2001 Nov;75(22):10958-68.

12.

In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb.

Puglielli MT, Zajac AJ, van der Most RG, Dzuris JL, Sette A, Altman JD, Ahmed R.

J Virol. 2001 Jun;75(11):5099-107.

13.

Gorillas with spondyloarthropathies express an MHC class I molecule with only limited sequence similarity to HLA-B27 that binds peptides with arginine at P2.

Urvater JA, Hickman H, Dzuris JL, Prilliman K, Allen TM, Schwartz KJ, Lorentzen D, Shufflebotham C, Collins EJ, Neiffer DL, Raphael B, Hildebrand W, Sette A, Watkins DI.

J Immunol. 2001 Mar 1;166(5):3334-44. Review.

14.

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Allen TM, Mothé BR, Sidney J, Jing P, Dzuris JL, Liebl ME, Vogel TU, O'Connor DH, Wang X, Wussow MC, Thomson JA, Altman JD, Watkins DI, Sette A.

J Virol. 2001 Jan;75(2):738-49.

15.

Definition of the Mamu A*01 peptide binding specificity: application to the identification of wild-type and optimized ligands from simian immunodeficiency virus regulatory proteins.

Sidney J, Dzuris JL, Newman MJ, Johnson RP, Kaur A, Amitinder K, Walker CM, Appella E, Mothe B, Watkins DI, Sette A.

J Immunol. 2000 Dec 1;165(11):6387-99. Erratum in: J Immunol 2001 Jan 15;166(2):following 1413.

16.

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothé BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI.

Nature. 2000 Sep 21;407(6802):386-90.

PMID:
11014195
17.

Conserved MHC class I peptide binding motif between humans and rhesus macaques.

Dzuris JL, Sidney J, Appella E, Chesnut RW, Watkins DI, Sette A.

J Immunol. 2000 Jan 1;164(1):283-91.

18.

Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Evans DT, O'Connor DH, Jing P, Dzuris JL, Sidney J, da Silva J, Allen TM, Horton H, Venham JE, Rudersdorf RA, Vogel T, Pauza CD, Bontrop RE, DeMars R, Sette A, Hughes AL, Watkins DI.

Nat Med. 1999 Nov;5(11):1270-6.

PMID:
10545993
19.

Expression of mouse mammary tumor virus envelope protein does not prevent superinfection in vivo or in vitro.

Dzuris JL, Zhu W, Kapkov D, Golovkina TV, Ross SR.

Virology. 1999 Oct 25;263(2):418-26.

20.

Both T and B cells shed infectious mouse mammary tumor virus.

Dzuris JL, Golovkina TV, Ross SR.

J Virol. 1997 Aug;71(8):6044-8.

21.

Inhibition of T cell activation by an autoantibody induced by murine retrovirus infection.

Townsend RM, Dzuris JL, Mirza I, Sieck T, Coffman F, Blank KJ.

Clin Immunol Immunopathol. 1997 Mar;82(3):263-73.

PMID:
9073550
22.

Mouse mammary tumor virus (MMTV), a retrovirus that exploits the immune system. Genetics of susceptibility to MMTV infection.

Ross SR, Dzuris JL, Golovkina TV, Clemmons WC, van den Hoogen B.

Medicina (B Aires). 1997;57 Suppl 2:34-42.

PMID:
9567342

Supplemental Content

Loading ...
Support Center